34.86
+0.17%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hansoh Pharmaceutical Group Company
Its shares trade on HKEX under the ticker 3692.HK. It has been listed since 14 June 2019. In the fiscal year to 31 December 2025, it reported revenue of CN¥17.49bn and net income of CN¥6.47bn. At that date it held total assets of CN¥46.45bn and shareholders' equity of CN¥41.17bn.
Hansoh Pharmaceutical Group Co., Ltd. is a holding company, which engages in the research and development, production, and sale of a series of pharmaceutical products. The company is headquartered in Lianyungang, Jiangsu. The company went IPO on 2019-06-14. The Company’s main products include Oulanning, Ameining, Pulaile, Zefei, Xinwei, Xinmei, Zetan, Mailingda, Hengjie, Hengsen, Fulaidi and Ruibote, among others. The Company’s products are mainly used for central nervous system disease, oncology, anti-infection, diabetes, digestive tract and cardiovascular treatment. The firm distributes its products in domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 14 Jun 2019
- Employees
- 9,178
- Website
- hspharm.com ↗
Leadership
Pay as last reported
- Ms. Huijuan ZhongExecutive Chairlady of the Board, Chief Executive Officer, since 2015CN¥14.8m
- Mr. Min HuChief Financial Officer
- Ms. Shengli ZhongSenior Vice President, Joint Company Secretary
- Mr. Chuanhe XuSenior Vice President
- Dr. Chih-Hung LeeChief Science Officer
- Mr. Yifeng LuVice President
- Mr. Aifeng LyuExecutive Director, since 2016CN¥9.4m
- Ms. Yuan SunExecutive Director, since 2015CN¥16.6m
- Mr. Weiyong SunChief Commercial Officer
- Ms. Yuen Ki WongJoint Company Secretary
- Mr. Sheung Wai ChanNon-Executive Independent DirectorCN¥360,000
- Mr. Guoqiang LinNon-Executive Independent DirectorCN¥360,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 88
- Environment
- 99
- Social
- 99
- Governance
- 66
- Direct emissions (scope 1)
- 13,163.25 t
- Energy emissions (scope 2)
- 88,227.05 t
- Value chain emissions (scope 3)
- 55,724.8 t
- Women in the workforce
- 39%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Established Brand Reputation: Hansoh Pharmaceutical Group Co Ltd has built a strong brand image in the pharmaceutical industry, known for its high-quality and reliable products.
- Diverse Product Portfolio: The company offers a wide range of pharmaceutical products across various therapeutic areas, catering to diverse customer needs.
- Strong Research and Development Capabilities: Hansoh invests significantly in research and development, leading to continuous innovation and the introduction of new drugs to the market.
- Extensive Distribution Network: With an extensive distribution network, the company can reach a vast customer base, both domestically and internationally.
Weaknesses
- Dependency on Key Products: Hansoh Pharmaceutical Group Co Ltd relies heavily on a few key products for a significant portion of its revenue, making it vulnerable to fluctuations in demand or patent expirations.
- Limited Global Presence: While the company has expanded its international reach, it still has a relatively limited global presence compared to some of its competitors.
- Regulatory Challenges: Operating in the pharmaceutical industry involves navigating strict regulations, which can pose challenges and delays in product approvals and market entry.
Opportunities
- Growing Healthcare Market: The increasing demand for healthcare services, particularly in emerging markets, presents an opportunity for Hansoh Pharmaceutical to expand its customer base and revenue.
- Emerging Technologies: Advances in technology, such as personalized medicine and digital health solutions, open up avenues for innovation and the development of new products and services.
- Strategic Partnerships and Collaborations: Collaborating with other pharmaceutical companies, research institutions, or technology firms can enhance Hansoh's capabilities and accelerate its growth.
Threats
- Intense Competitive Landscape: The pharmaceutical industry is highly competitive, with numerous established players and new entrants vying for market share.
- Stringent Regulatory Environment: Regulatory changes or compliance issues can impact the company's operations, requiring significant resources and potentially affecting profitability.
- Patent Expirations and Generic Competition: The expiration of patents for key drugs can lead to increased competition from generic alternatives, potentially eroding Hansoh's market share and revenue.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.